Epinephrine Promotes IL-8 Production in Human Leukocytes via an Effect on Platelets

Summary

Interleukin-8 (IL-8) is generally accepted to be an important mediator of a number of acute and chronic inflammatory diseases and is produced by monocytes upon stimulation by lipopolysaccharide (LPS). Epinephrine has been reported by several groups to suppress activation of monocytes in response to LPS, and the aim of the present study was to examine the effect of epinephrine on LPS induced IL-8 production using whole blood as a model system. Epinephrine increased LPS induced IL-8 production in a dose-dependent manner in the whole concentration range (0.001–100 μM) and 1 μM epinephrine increased IL-8 levels with 125%. Epinephrine per se had no effect on IL-8 levels. The potentiating effect of epinephrine was mediated by blood platelets, since IL-8 levels in samples containing platelets and stimulated with LPS and epinephrine (1–100 μM) were significantly higher (p <0.05) than in control samples containing no platelets. This effect of platelets seemed to be due to platelet release products, since addition of 25 μl platelet lysate supernatant to whole blood increased LPS induced IL-8 production with 100% and a similar effect was observed in freshly isolated mononuclear cells resuspended in plasma. Upon addition of 50 μg/ml of the carboxyterminal peptide of platelet factor 4 (PF4(58-70)) to whole blood, LPS stimulated IL-8 levels were increased with 115%, whereas in mononuclear cells, 20 μg/ml PF4(58-70) enhanced IL-8 production with 40%. We demonstrate for the first time that epinephrine promotes LPS induced production of IL-8 in whole blood via an effect on blood platelets. This potentiating effect of platelets is shown to be due to platelet granule contents, and platelet factor 4 (PF4) is suggested to be one of several platelet granule proteins promoting LPS induced IL-8 production in whole blood.

^* Both authors have contributed equally to this paper

• References

• 1 Walz A, Peveri P, Aschauer H, Baggiolini M. Purification and amino acid sequencing of NAF, a novel neutrophil-activating factor produced by monocytes. Biochem Biophys Res Commun 1987; 149: 755-61.
• 2 Yoshimura T, Matsushima K, Kanaka S, Robinson EA, Apella E, Oppenheim JJ, Leonard EJ. Purification of a human monocyte-derived neutrophil chemotactic factor that has peptide sequence similarity to other host defense cytokines. Proc Natl Acad Sci USA 1987; 84: 9233-7.
• 3 Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines – CXC and CC chemokines. Adv 1994; 55: 97-179.
• 4 Harada A, Mukaida N, Matsushima K. Interleukin-8 as a novel target for intervention therapy in acute inflammatory diseases. Mol Med Today 1996; 2: 482-9.
• 5 Sekut L, Champion BR, Page K, Menius JA, Connolly KM. Anti-inflammatory activity of salmeterol: down-regulation of cytokine production. Clin Exp Immunol 1995; 99: 461-6.
• 6 Severn A, Rapson TR, Hunter CA, Liew FY. Regulation of tumor necrosis factor production by adrenaline and β-adrenergic agonists. J Immunol 1992; 148: 3441-5.
• 7 van der Poll T, Coyle SM, Barbosa K, Braxton CC, Lowry SF. Epinephrine inhibits tumor necrosis factor-α and potentiates interleukin 10 production during human endotoxemia. J Clin Invest 1996; 97: 713-9.
• 8 Watson F, Robinson JJ, Edwards SW. Neutrophil function in whole blood and after purification: Changes in receptor expression, oxidase activity and responsiveness to cytokines. Biosci Rep 1992; 12: 123-33.
• 9 van Ginkel GJ, van Aken WG, Oh I J, Vreeken J. Stimulation of monocyte procoagulant activity by adherence to different surfaces. Br J Haematol 1977; 37: 35-45.
• 10 Haskill S, Johnson C, Eierman D, Becker S, Warren K. Adherence induces selectively mRNA expression of monocyte mediators and proto-oncogenes. J Immunol 1988; 140: 1690-4.
• 11 Hofsli E, Lamvik J, Nissen-Meyer J. Evidence that tumour necrosis factor (TNF) is not constitutively present in vivo. Scand J Immunol 1988; 28: 435-41.
• 12 Sporn SA, Eierman DF, Johnson CE, Morris J, Martin G, Ladner M, Haskill S. Monocyte adherence results in selective induction of novel genes sharing homology with mediators of inflammation and tissue repair. J Immunol 1990; 144: 4434-41.
• 13 de Groote D, Zangerle PF, Gevaert Y, Fassotte MF, Beguin Y, Noizat-Pirenne F, Gathy R, Lopez M, Dehart I, Igot D, Baudrihaye M, Delacroix D, Franchimont P. Direct stimulation of cytokines (IL1-β, TNF-α, IL-6, IFN-γ and GM-CSF) in whole blood. I. Comparison with isolated PBMC stimulation. Cytokine 1992; 4: 239-48.
• 14 Kasahara K, Strieter RM, Chensue SW, Standiford TJ, Kunkel SL. Mononuclear cell adherence induces neutrophil chemotactic factor/Interleukin-8 gene expression. J Leuk Biol 1991; 50: 287-95.
• 15 Engstad CS, Lia K, Rekdal Ø, Olsen JO, Østerud B. A novel biological effect of platelet factor 4 (PF4): Enhancement of LPS-induced tissue factor activity in monocytes. J Leuk Biol 1995; 58: 575-81.
• 16 Shattil SJ, Budzynski A, Scrutton MC. Epinephrine induces platelet fibrin-ogen receptor expression, fibrinogen binding, and aggregation in whole blood in the absence of other excitatory agonists. Blood 1989; 73: 150-8.
• 17 Sanderson HM, Heptinstall S, Vickers J, Loesche W. Studies on the effects of agonists and antagonists on platelet shape change and platelet aggregation in whole blood. Blood Coagul Fibrinol 1996; 7: 245-8.
• 18 Anfossi G, Trovati M. Role of catecholamines in platelet function: patho-physiological and clinical significance. Eur J Clin Invest 1996; 26: 353-70.
• 19 Bazzoni F, Cassatella MA, Rossi F, Ceska M, Dewald B, Baggiolini M. Phagocytosing neutrophils produce and release high amounts of the neutrophil-activating peptide 1/Interleukin-8. J Exp Med 1991; 173: 771-4.
• 20 Altstaedt J, Kirchner H, Rink L. Cytokine production of neutrophils is limited to interleukin-8. Immunology 1996; 89: 563-8.
• 21 Aziz KA, Cawley JC, Zuzel M. Platelets prime PMN via released PF4: mechanism of priming and synergy with GM-CSF. Br J Haematol 1995; 91: 846-53.
• 22 Zucker MB, Katz IR. Platelet factor 4: Production, structure, and physiologic and immunologic action. Proc Soc Exp Biol Med 1991; 198: 693-702.
• 23 Sozzani S, Locati M, Allavena A, van Damme J, Mantovani A. Chemo-kines: a superfamily of chemotactic cytokines. Int J Clin Lab Res 1996; 26: 69-82
• 24 Liebler JM, Kunkel SL, Burdick MD, Standiford TJ, Rolfe MW, Strieter RM. Production of IL-8 and monocyte chemotactic peptide-1 by peripheral blood monocytes. J Immunol 1994; 152: 241-9.
• 25 DeForge LE, Kenney JS, Jones ML, Warrren JS, Remick DG. Biphasic production of IL-8 in lipopolysaccharide (LPS)-stimulated human whole blood. J Immunol 1992; 148: 2133-41.
• 26 Halvorsen H, Olsen JO. Østerud B: Granulocytes enhance LPS-induced tissue factor activity in monocytes via an interaction with platelets. J Leuk Biol 1993; 54: 275-82.
• 27 Steen VM, Holmsen H, Aarbakke G. The platelet-stimulating effect of adrenaline through α2-adrenergic receptors requires simultaneous activation by a true platelet stimulatory agonist. Thromb Haemost 1993; 70: 506-13.
• 28 Kjeldsen SE, Weder AB, Egan B, Neubig R, Zweifler AJ, Julius S. Effect of circulating epinephrine on platelet function and hematocrit. Hypertension 1995; 25: 1096-105.
• 29 Nakamura T, Ariyoshi H, Kambayashi J, Ikeda M, Shinoki N, Kawasaki T, Monden M. Signal transduction system in epinephrine stimulated platelets; comparison between epinephrine sensitive and insensitive platelets. Thromb Res 1997; 85: 83-93.
• 30 Crovello CS, Furie BC, Furie B. Rapid phosphorylation and dephosphorylation of P-selectin accompanies platelet activation. J Biol Chem 1993; 268: 14590-3.
• 31 Goto S, Handa S, Takahashi E, Abe S, Handa M, Ikeda Y. Synergistic effect of epinephrine and shearing on platelet activation. Thromb Res 1996; 84: 351-9.
• 32 Larsson PT, Wallen NH, Egberg N, Hjemdahl P. α-Adrenoceptor blockade by phentolamine inhibits adrenaline-induced platelet activation in vivo without affecting resting measurements. Clin Sci 1992; 82: 369-76.
• 33 Lande K, Kjeldsen SE, Os I, Westheim A, Hjermann I, Eide I, Gjesdal K. Increased platelet and vascular smooth muscle reactivity to low-dose adrenaline infusion in mild essential hypertension. J Hypertension 1988; 6: 219-25.
• 34 Sims PJ, Wiedmer T. Induction of cellular procoagulant activity by the membrane attack complex of complement. Semin Cell Biol 1995; 6: 275-82.
• 35 Gregory H, Young J, Schroeder JM, Mrowietz U, Christophers E. Structure determination of a human lymphocyte derived neutrophil activating peptide (LYNAP). Biochem Biophys Res Commun 1988; 151: 883-90
• 36 Strieter RM, Chensue SW, Standiford TJ, Basha MA, Showell HJ, Kunkel SL. Disparate gene expression of chemotactic cytokines by human mononuclear phagocytes. Biochem Biophys Res Commun 1990; 166: 886-91.
• 37 Smyth MJ, Zachariae COC, Norihisa Y, Ortaldo JR, Hishinuma A, Matsushima K. IL-8 gene expression and production in human peripheral blood lymphocyte subsets. J Immunol 1991; 146: 3815-23.
• 38 Weyrich AS, Elstad MR, McEver RP, McIntyre TM, Moore KL, Morrissey JH, Prescott SM, Zimmerman GA. Activated platelets signal chemokine synthesis by human monocytes. J Clin Invest 1996; 97: 1525-34.
• 39 Deuel TF, Senior RM, Chang D, Griffin GL, Heinrikson RL, Kaiser ET. Platelet factor 4 is chemotactic for neutrophils and monocytes. Proc Natl Acad Sci USA 1981; 78: 4584-7.
• 40 Osterman DG, Griffin GL, Senior RM, Kaiser ET, Deuel TF. The carboxyl-terminal tridecapeptide of platelet factor 4 is a potent chemotactic agent for monocytes. Biochem Biophys Res Commun 1982; 1078: 130-5.
• 41 Uhlin-Hansen L, Langvoll D, Kolset SO. Blood platelets stimulate the expression of chondroitin sulfate proteoglycan in human monocytes. Blood 1992; 80: 1058-65.